GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Australian Clinical Labs Ltd (ASX:ACL) » Definitions » Net Current Asset Value

Australian Clinical Labs (ASX:ACL) Net Current Asset Value : A$-1.46 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Australian Clinical Labs Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Australian Clinical Labs's net current asset value per share for the quarter that ended in Dec. 2023 was A$-1.46.

The historical rank and industry rank for Australian Clinical Labs's Net Current Asset Value or its related term are showing as below:

ASX:ACL's Price-to-Net-Current-Asset-Value is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 4.27
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Australian Clinical Labs Net Current Asset Value Historical Data

The historical data trend for Australian Clinical Labs's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Australian Clinical Labs Net Current Asset Value Chart

Australian Clinical Labs Annual Data
Trend Dec20 Jun21 Jun22 Jun23
Net Current Asset Value
-1.36 -1.37 -1.25 -1.44

Australian Clinical Labs Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Current Asset Value Get a 7-Day Free Trial -1.27 -1.25 -1.49 -1.44 -1.46

Competitive Comparison of Australian Clinical Labs's Net Current Asset Value

For the Diagnostics & Research subindustry, Australian Clinical Labs's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Australian Clinical Labs's Price-to-Net-Current-Asset-Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Australian Clinical Labs's Price-to-Net-Current-Asset-Value falls into.



Australian Clinical Labs Net Current Asset Value Calculation

Australian Clinical Labs's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Jun. 2023 is calculated as

Net Current Asset Value Per Share(A: Jun. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(115.959-406.242-0.254-0)/201.834
=-1.44

Australian Clinical Labs's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(Q: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(125.761-418.693-0.202-0)/200.503
=-1.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Australian Clinical Labs  (ASX:ACL) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Australian Clinical Labs Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Australian Clinical Labs's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Australian Clinical Labs (ASX:ACL) Business Description

Traded in Other Exchanges
N/A
Address
1868-1892 Dandenong Road, Clayton, VIC, AUS, 3168
Australian Clinical Labs, or ACL, is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well-established in the states of Western Australia, South Australia, Victoria and the Northern Territory.

Australian Clinical Labs (ASX:ACL) Headlines

No Headlines